{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:39:41Z","timestamp":1794591581907,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This research was supported by anonymous philanthropic support to the Broad Institute."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41591-019-0749-z","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T12:04:02Z","timestamp":1581336242000},"page":"181-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":269,"title":["The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research"],"prefix":"10.1038","volume":"26","author":[{"given":"Corrie A.","family":"Painter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1201-2052","authenticated-orcid":false,"given":"Esha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett N.","family":"Tomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dunphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beena S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa L.","family":"Damon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrayz","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewey","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"G\u00f3mez Tejeda Za\u00f1udo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Merriam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrajit P.","family":"Raut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Demetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Van Tine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0113-2403","authenticated-orcid":false,"given":"Todd R.","family":"Golub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-9438","authenticated-orcid":false,"given":"Nikhil","family":"Wagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"749_CR1","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.chembiol.2017.08.002","volume":"24","author":"T Sharifnia","year":"2017","unstructured":"Sharifnia, T., Hong, A. L., Painter, C. A. & Boehm, J. S. Emerging opportunities for target discovery in rare cancers. Cell Chem. Biol. 24, 1075\u20131091 (2017).","journal-title":"Cell Chem. Biol."},{"key":"749_CR2","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/SLA.0b013e3181dbb75a","volume":"251","author":"G Lahat","year":"2010","unstructured":"Lahat, G. et al. Angiosarcoma: clinical and molecular insights. Ann. Surg. 251, 1098\u20131106 (2010).","journal-title":"Ann. Surg."},{"key":"749_CR3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/CMAR.S159641","volume":"10","author":"NT Hoang","year":"2018","unstructured":"Hoang, N. T., Acevedo, L. A., Mann, M. J. & Tolani, B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag. Res. 10, 1089\u20131114 (2018).","journal-title":"Cancer Manag. Res."},{"key":"749_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13569-017-0081-7","volume":"7","author":"RB Cohen-Hallaleh","year":"2017","unstructured":"Cohen-Hallaleh, R. B. et al. Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. Clin. Sarcoma Res. 7, 15 (2017).","journal-title":"Clin. Sarcoma Res."},{"key":"749_CR5","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/S0140-6736(74)90683-7","volume":"1","author":"FI Lee","year":"1974","unstructured":"Lee, F. I. & Harry, D. S. Angiosarcoma of the liver in a vinyl-chloride worker. Lancet 1, 1316\u20131318 (1974).","journal-title":"Lancet"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/ng.2921","volume":"46","author":"S Behjati","year":"2014","unstructured":"Behjati, S. et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat. Genet. 46, 376\u2013379 (2014).","journal-title":"Nat. Genet."},{"key":"749_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/gcc.20827","volume":"50","author":"T Guo","year":"2011","unstructured":"Guo, T. et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 50, 25\u201333 (2011).","journal-title":"Genes Chromosomes Cancer"},{"key":"749_CR8","first-page":"28","volume":"3","author":"TK Arora","year":"2014","unstructured":"Arora, T. K., Terracina, K. P., Soong, J., Idowu, M. O. & Takabe, K. Primary and secondary angiosarcoma of the breast. Gland Surg. 3, 28\u201334 (2014).","journal-title":"Gland Surg."},{"key":"749_CR9","doi-asserted-by":"publisher","first-page":"e1003464","DOI":"10.1371\/journal.pgen.1003464","volume":"9","author":"CP Giacomini","year":"2013","unstructured":"Giacomini, C. P. et al. Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. PLoS Genet. 9, e1003464 (2013).","journal-title":"PLoS Genet."},{"key":"749_CR10","doi-asserted-by":"publisher","first-page":"36041","DOI":"10.18632\/oncotarget.5936","volume":"6","author":"R Murali","year":"2015","unstructured":"Murali, R. et al. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget 6, 36041\u201336052 (2015).","journal-title":"Oncotarget"},{"key":"749_CR11","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.1158\/0008-5472.CAN-14-1162","volume":"74","author":"K Kunze","year":"2014","unstructured":"Kunze, K. et al. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells. Cancer Res. 74, 6173\u20136183 (2014).","journal-title":"Cancer Res."},{"key":"749_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/modpathol.2013.163","volume":"27","author":"W Shon","year":"2014","unstructured":"Shon, W., Sukov, W. R., Jenkins, S. M. & Folpe, A. L. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study. Mod. Pathol. 27, 509\u2013515 (2014).","journal-title":"Mod. Pathol."},{"key":"749_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"749_CR14","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1002\/cncr.27614","volume":"118","author":"A Italiano","year":"2012","unstructured":"Italiano, A. et al. Alterations of the p53 and PIK3CA\/AKT\/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 118, 5878\u20135887 (2012).","journal-title":"Cancer"},{"key":"749_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","volume":"8","author":"MT Chang","year":"2018","unstructured":"Chang, M. T. et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 8, 174\u2013183 (2018).","journal-title":"Cancer Discov."},{"key":"749_CR16","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1038\/onc.2011.532","volume":"31","author":"WC Hon","year":"2012","unstructured":"Hon, W. C., Berndt, A. & Williams, R. L. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene 31, 3655\u20133666 (2012).","journal-title":"Oncogene"},{"key":"749_CR17","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1158\/0008-5472.CAN-15-1654","volume":"75","author":"T Dogruluk","year":"2015","unstructured":"Dogruluk, T. et al. Identification of variant-specific functions of PIK3CA by rapid phenotyping of rare mutations. Cancer Res. 75, 5341\u20135354 (2015).","journal-title":"Cancer Res."},{"key":"749_CR18","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1073\/pnas.0701005104","volume":"104","author":"M Gymnopoulos","year":"2007","unstructured":"Gymnopoulos, M., Elsliger, M. A. & Vogt, P. K. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl Acad. Sci. USA 104, 5569\u20135574 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"749_CR19","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-04-4114","volume":"65","author":"T Ikenoue","year":"2005","unstructured":"Ikenoue, T. et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65, 4562\u20134567 (2005).","journal-title":"Cancer Res."},{"key":"749_CR20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre, F. et al. Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"749_CR21","unstructured":"Juric, D. et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial. JAMA Oncol. 5, e184475 (2018)."},{"key":"749_CR22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","volume":"36","author":"D Juric","year":"2018","unstructured":"Juric, D. et al. Phosphatidylinositol 3-kinase alpha-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J. Clin. Oncol. 36, 1291\u20131299 (2018).","journal-title":"J. Clin. Oncol."},{"key":"749_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"749_CR24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","volume":"163","author":"G Ciriello","year":"2015","unstructured":"Ciriello, G. et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163, 506\u2013519 (2015).","journal-title":"Cell"},{"key":"749_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"749_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"Cancer Genome Atlas Research Network.","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950\u2013965 e28 (2017).","journal-title":"Cell"},{"key":"749_CR27","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","volume":"171","author":"BB Campbell","year":"2017","unstructured":"Campbell, B. B. et al. Comprehensive analysis of hypermutation in human cancer. Cell 171, 1042\u20131056 e10 (2017).","journal-title":"Cell"},{"key":"749_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713 (2017).","journal-title":"Nat. Med."},{"key":"749_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/modpathol.2013.168","volume":"27","author":"KG Griewank","year":"2014","unstructured":"Griewank, K. G. et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod. Pathol. 27, 502\u2013508 (2014).","journal-title":"Mod. Pathol."},{"key":"749_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1055\/s-0035-1547520","volume":"19","author":"B Mullins","year":"2015","unstructured":"Mullins, B. & Hackman, T. Angiosarcoma of the head and neck. Int. Arch. Otorhinolaryngol. 19, 191\u2013195 (2015).","journal-title":"Int. Arch. Otorhinolaryngol."},{"key":"749_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ijos.2012.36","volume":"4","author":"R Karube","year":"2012","unstructured":"Karube, R. et al. Angiosarcoma of the scalp diagnosed by the presence of neck inflammation: a case report. Int. J. Oral Sci. 4, 166\u2013169 (2012).","journal-title":"Int. J. Oral Sci."},{"key":"749_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"749_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0605-7","volume":"10","author":"JR Conway","year":"2018","unstructured":"Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H. & Van Allen, E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med. 10, 93 (2018).","journal-title":"Genome Med."},{"key":"749_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"749_CR35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263 (2012).","journal-title":"Cell"},{"key":"749_CR36","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"749_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"749_CR38","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","volume":"31","author":"N van Rooij","year":"2013","unstructured":"van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439\u2013e442 (2013).","journal-title":"J. Clin. Oncol."},{"key":"749_CR39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine, R. L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387\u2013397 (2005).","journal-title":"Cancer Cell"},{"key":"749_CR40","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1158\/1078-0432.CCR-09-2437","volume":"16","author":"N Girard","year":"2010","unstructured":"Girard, N. et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an internet-based blood collection protocol: a preliminary report. Clin. Cancer Res. 16, 755\u2013763 (2010).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0749-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0749-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:01:10Z","timestamp":1684605670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-019-0749-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1038\/s41591-019-0749-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/741744","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"10 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.P. is a nominal stockholder in Supernus Pharmaceuticals. C.A.P. has received sponsored research support from Eisai Inc. J.L.H. is a consultant to Eli Lilly and Epizyme. G.D.D. reports the following interests: grants, personal fees, non-financial support and travel support to consulting meetings from Novartis, Bayer, Roche, Epizyme and Daiichi-Sankyo; grants, personal fees and travel support to consulting meetings from Pfizer; personal fees and travel support to consulting meetings from EMD-Serono; personal fees from Sanofi; grants and personal fees from Ignyta; grants, personal fees and travel support to consulting meetings from Loxo Oncology; grants, personal fees and non-financial support from AbbVie; personal fees and travel support to consulting meetings from Mirati Therapeutics; personal fees and travel support to consulting meetings from WIRB Copernicus Group; personal fees from ZioPharm; personal fees from Polaris Pharmaceuticals; personal fees and travel support to consulting meetings from M.J. Hennessey\/OncLive; grants, personal fees and travel support to consulting meetings from Adaptimmune; grants from GlaxoSmithKline; personal fees, minor equity, and travel support to Board meetings from Blueprint Medicines, where he serves as a member of the Board of Directors; personal fees and minor equity options from Merrimack Pharmaceuticals, where he serves as a member of the Board of Directors; personal fees and minor equity from G1 Therapeutics; personal fees, minor equity options and travel support to consulting meetings from CARIS Life Sciences; minor equity options from Bessor Pharmaceuticals; minor equity options from ERASCA Pharmaceuticals; personal fees and travel support to consulting meetings from CHAMPIONS Oncology; grants and personal fees from Janssen; grants, personal fees, travel support to consulting meetings, and non-financial support from PharmaMar. In addition, G.D.D. has a use patent on imatinib for GIST, licensed to Novartis with royalties paid to the Dana-Farber Cancer Institute. E.S.L. serves on the Board of Directors for Codiak BioSciences and Neon Therapeutics, and serves on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; he is also affiliated with several non-profit organizations including serving on the Board of Directors of the Innocence Project, Count Me In, and Biden Cancer Initiative, and the Board of Trustees for the Parker Institute for Cancer Immunotherapy. E.S.L. has served and continues to serve on various federal advisory committees. T.R.G. serves or has recently served as a scientific adviser to Foundation Medicine, Inc. (wholly owned by Roche), GlaxoSmithKline, plc, Sherlock Biosciences, Inc., and FORMA Therapeutics, Inc. N.W. was previously a stockholder and consultant for Foundation Medicine, Inc., has been a consultant\/advisor for Novartis and Eli Lilly, and has received sponsored research support from Novartis and Puma Biotechnology. None of the for-profit entities had any role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}